

Mark B Efron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9120508/publications.pdf>

Version: 2024-02-01

94
papers

4,742
citations

101384

36
h-index

95083

68
g-index

112
all docs

112
docs citations

112
times ranked

4347
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction. <i>Circulation</i> , 1998, 98, 734-741.	1.6	679
2	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2205-2217.	13.9	596
3	Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial. <i>Stroke</i> , 2008, 39, 87-99.	1.0	362
4	A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes Mellitus (OPTIMUS)-3 Trial. <i>European Heart Journal</i> , 2011, 32, 838-846.	1.0	178
5	Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1017-1023.	1.2	160
6	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1981-1990.	13.9	145
7	Abciximab Readministration. <i>Circulation</i> , 2001, 104, 870-875.	1.6	143
8	Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction. <i>Circulation</i> , 2003, 108, 1316-1323.	1.6	143
9	Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm. <i>American Journal of Cardiology</i> , 1988, 62, 1202-1207.	0.7	112
10	Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial. <i>Circulation</i> , 2009, 119, 922-930.	1.6	102
11	Effects of Integrelin, a Platelet Glycoprotein IIb/IIIa Receptor Antagonist, in Unstable Angina. <i>Circulation</i> , 1996, 94, 2083-2089.	1.6	90
12	Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1880-1889.	1.1	87
13	Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1500-1509.	1.2	85
14	Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. <i>Annals of Thoracic Surgery</i> , 2000, 70, 516-526.	0.7	80
15	Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 917-924.	1.1	76
16	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 499-508.	0.4	68
17	Impact of In-Hospital Acquired Thrombocytopenia in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2005, 96, 474-481.	0.7	64
18	Antibiotic Overuse: The Influence of Social Norms. <i>Journal of the American College of Surgeons</i> , 2008, 207, 265-275.	0.2	63

#	ARTICLE	IF	CITATIONS
19	Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. <i>American Heart Journal</i> , 2017, 183, 62-68.	1.2	60
20	Treating Patients With "Wake-Up" Stroke. <i>Stroke</i> , 2008, 39, 3277-3282.	1.0	59
21	1-Year Survival in a Randomized Trial of Facilitated Reperfusion. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 909-916.	1.1	59
22	Rationale and Design of the Aspirin Dosing "A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. <i>JAMA Cardiology</i> , 2020, 5, 598.	3.0	59
23	Elastic properties of the human chest during cardiopulmonary resuscitation. <i>Critical Care Medicine</i> , 1983, 11, 685-692.	0.4	57
24	Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 629-637.	0.7	56
25	Early Medication Nonadherence After Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 347-356.	0.9	55
26	"Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 535-544.	0.7	55
27	Treatment with Adenosine Diphosphate Receptor Inhibitors "Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research. <i>American Heart Journal</i> , 2011, 162, 844-851.	1.2	51
28	Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 750.	3.0	50
29	Impact of Bleeding on Quality of Life in Patients on DAPT. <i>Journal of the American College of Cardiology</i> , 2016, 67, 59-65.	1.2	48
30	Final results of the ReoPro readministration registry. <i>American Journal of Cardiology</i> , 2004, 93, 979-984.	0.7	47
31	Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction. <i>Circulation</i> , 2015, 132, 174-181.	1.6	45
32	Effects of Abciximab, Ticlopidine, and Combined Abciximab/Ticlopidine Therapy on Platelet and Leukocyte Function in Patients Undergoing Coronary Angioplasty. <i>Circulation</i> , 2000, 101, 1122-1129.	1.6	42
33	Effect on Platelet Reactivity From a Prasugrel Loading Dose After a Clopidogrel Loading Dose Compared With a Prasugrel Loading Dose Alone. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 567-574.	1.4	42
34	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2017-2025.	1.1	41
35	Effects of resistive training on left ventricular function. <i>Medicine and Science in Sports and Exercise</i> , 1989, 21, 694.	0.2	38
36	Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 203-212.	1.1	37

#	ARTICLE	IF	CITATIONS
37	A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, S33-S61.	1.3	35
38	Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. <i>American Journal of Cardiology</i> , 1999, 84, 728-730.	0.7	27
39	Readministration of abciximab: Interim report of the ReoPro Readministration Registry. <i>American Heart Journal</i> , 1999, 138, s33-s38.	1.2	26
40	Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction. <i>Circulation</i> , 2016, 133, 493-501.	1.6	26
41	Adherence and Persistence with Prasugrel Following Acute Coronary Syndrome with Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 263-271.	1.0	25
42	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017, 188, 73-81.	1.2	25
43	Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. <i>Current Medical Research and Opinion</i> , 2014, 30, 2207-2216.	0.9	23
44	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 319-329.	0.8	22
45	One-Year Post-Discharge Resource Utilization and Treatment Patterns of Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Treated with Ticagrelor or Prasugrel. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 337-350.	1.0	21
46	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 459-468.	1.1	19
47	Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study. <i>Thrombosis and Haemostasis</i> , 2013, 109, 347-355.	1.8	19
48	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	19
49	Platelet Glycoprotein IIb/IIIa Receptor Antagonists And Their Use In Elderly Patients. <i>Drugs and Aging</i> , 2000, 16, 179-187.	1.3	18
50	Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. <i>American Heart Journal</i> , 2000, 140, 492-501.	1.2	17
51	Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). <i>American Journal of Cardiology</i> , 2003, 92, 779-784.	0.7	17
52	The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 317-324.	0.8	16
53	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001712.	1.4	16
54	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E112-E119.	0.7	16

#	ARTICLE	IF	CITATIONS
55	Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	14
56	Association of measured platelet reactivity with changes in P2Y ₁₂ receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the Treatment with ADP receptor inhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. <i>American Heart Journal</i> , 2017, 187, 19-28.	1.2	14
57	Multivessel Versus Culprit Vessel-Only Percutaneous Coronary Intervention Among Patients With Acute Myocardial Infarction: Insights From the TRANSLATE-ACS Observational Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	14
58	Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 48, 430-434.	0.7	13
59	Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1223-1231.	1.8	12
60	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2019, 275, 31-35.	0.8	12
61	Two-dimensional echocardiographic features diagnostic of isolated pulmonic valve endocarditis. <i>American Heart Journal</i> , 1982, 103, 137-139.	1.2	11
62	How Reliable are Patient-Reported Rehospitalizations? Implications for the Design of Future Practical Clinical Studies. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	11
63	Early Post-Discharge Bleeding and Antiplatelet Therapy Discontinuation Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1700-1702.	1.2	10
64	Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor. <i>Journal of Medical Economics</i> , 2015, 18, 898-908.	1.0	9
65	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	9
66	Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. <i>Thrombosis and Haemostasis</i> , 2014, 112, 311-322.	1.8	7
67	Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy - "Real World" Experience. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 531-536.	1.6	7
68	Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 2664-2671.	0.5	5
69	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. <i>American Heart Journal</i> , 2015, 170, 706-714.	1.2	5
70	One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 129-141.	1.0	5
71	Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E204-E210.	0.7	5
72	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 885-892.	0.7	5

#	ARTICLE	IF	CITATIONS
73	Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. <i>Clinical Research in Cardiology</i> , 2020, 109, 725-734.	1.5	5
74	Abciximab Reduces Urgent Target Vessel Revascularization at 30 Days After Primary Angioplasty, Independently of Acute Angiographic Results. The RAPPORT Trial. <i>Journal of the American College of Cardiology</i> , 1998, 31, 54A.	1.2	5
75	Safety of Readministration of Abciximab; Interim Results of the ReoPro Readministration Registry (R3). <i>Journal of the American College of Cardiology</i> , 1998, 31, 55A.	1.2	5
76	A prospective, observational study of Xigris Use in the United States (XEUS). <i>Journal of Critical Care</i> , 2010, 25, 660.e9-660.e16.	1.0	4
77	The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: insights from the TRANSLATE-ACS study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 242-250.	0.7	4
78	Abciximab Reduces the Need for Bail-out Stenting During Primary Angioplasty. The RAPPORT Trial. <i>Journal of the American College of Cardiology</i> , 1998, 31, 237A.	1.2	4
79	False positive signal-averaged ECG produced by junctional rhythm with retrograde P waves. <i>American Heart Journal</i> , 1992, 123, 1701-1703.	1.2	3
80	Safety Of Drotrecogin Alfa (Activated): Results Of XEUS, A Prospective Multicenter Observational Study. <i>Chest</i> , 2004, 126, 724S.	0.4	2
81	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor) Trial. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1414-1424.	1.6	2
82	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 53-60.	0.7	2
83	Synergy of Abciximab and Ticlopidine in Patients Undergoing Intracoronary Stenting. <i>Journal of the American College of Cardiology</i> , 1998, 31, 238A.	1.2	2
84	Hemodynamic vascular forces contribute to impaired endothelium-dependent vasodilation in reperfused canine epicardial coronary arteries. <i>Journal of the American College of Cardiology</i> , 1994, 23, 1216-1223.	1.2	1
85	Clinical Use Of Drotrecogin Alfa (Activated): Patients Treated In The XEUS Study Differ From High Risk PROWESS Patients. <i>Chest</i> , 2004, 126, 865S.	0.4	1
86	PCV86 COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS. <i>Value in Health</i> , 2008, 11, A408.	0.1	1
87	Response to Letter Regarding Article "Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in the Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors". <i>Circulation</i> , 2009, 120, .	1.6	1
88	Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 395-403.	0.5	1
89	Evidence for Enrollment Selection Bias in Trials of Primary Angioplasty: Comparison of GUSTO IIb and RAPPORT. <i>Journal of the American College of Cardiology</i> , 1998, 31, 231A.	1.2	1
90	PCV35 PRASUGREL AND CLOPIDOGREL PERSISTENCE AND DISCONTINUATION AMONG LOWER BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES. <i>Value in Health</i> , 2009, 12, A318.	0.1	0

#	ARTICLE	IF	CITATIONS
91	PCV126 REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIA. <i>Value in Health</i> , 2009, 12, A336.	0.1	0
92	TCT-723 Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients: High on-Treatment Platelet Reactivity Analysis of the TRIPLET Trial. <i>Journal of the American College of Cardiology</i> , 2012, 60, B211.	1.2	0
93	EFFICACY AND SAFETY OF PRETREATMENT AONG CONTEMPORARY ACUTE MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY. <i>Journal of the American College of Cardiology</i> , 2014, 63, A101.	1.2	0
94	Abstract 13544: Cardiologist Underutilization of New Antihyperglycemic Medications in Diabetic Patients With Cardiovascular Disease. <i>Circulation</i> , 2020, 142, .	1.6	0